fibromyalgia
FIBROMYALGIA

Fibromyalgia is a clinical syndrome wherein the patient experiences generalized pain and fatigue that cannot be explained by the presence of any other disorder.
It is often considered to be psychosomatic or psychogenic in nature.
It is found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 year of age

Fibromyalgia Signs and Symptoms

Introduction

  • A syndrome of chronic diffuse pain syndromes that affect muscles, soft tissues (eg tendons, ligaments) and other somatic symptoms
  • May be related to alterations in the central nervous system pain processing
  • Found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 years of age

Etiology

  • Etiology of pain is not known; often considered to be psychosomatic or psychogenic in nature

Signs and Symptoms

Clinical Manifestations

  • Widespread pain - initially localized then later involving multiple sites, predominantly involving muscles, musculoskeletal junctions and joints
  • Fatigue
  • Disrupted unrefreshed sleep
  • Cognitive disturbances - often referred to as “fibro fog”
  • Mood disturbances
  • Somatic symptoms (eg irritable bowel syndrome, severe menstrual pain, myofascial facial pain)
  • Non-pain related symptoms (sexual dysfunction)

Associated Symptoms

  • Paresthesias
  • Headache - include migraine and muscular or tension type
  • Anxiety and depression
  • Allergic symptoms and multiple chemical sensitivity
  • Weight disturbances
  • Pelvic pain, urinary frequency and urgency, and dysmenorrhea
  • Symptoms of irritable bowel syndrome
  • Sjogren symptoms
  • Raynaud’s phenomenon
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
09 Sep 2020
Advanced chronic kidney disease (CKD) associated with lupus nephritis (LN) does not necessarily lead to a need for dialysis, suggests a study, which shows majority of its patients (62 percent) not progressing over 10 year of follow-up on average.